Our transformative companies

Discover our portfolio of companies making an impact in regenerative medicine

Portfolio

Explore our portfolio of groundbreaking companies.

Restoring the natural balance to the immune system to treat autoimmune diseases.

Enhancing neuronal function and repair by restoring functional inhibition to treat CNS diseases.

Activating endogenous immune mechanisms to eliminate senescent cells.

Inhibiting HDAC6 to stabilize microtubules and enhance intracellular transport.

Novel modalities for thymic regeneration and immune system reconstitution.

Developing regulatory T cell therapies to manage immune tolerance.

Engineering thymopoietics to induce thymus rejuvenation.

Our focus

Fueling Innovation in Regenerative Medicine Startups.

At Eos, we pride ourselves in nurturing early-stage companies from concept to launch. Our incubation model provides the essential resources and guidance needed for success in the dynamic field of regenerative medicine.

Strategic Support

Our strategic and tactical support benefits our porfolio companies throughout their lifetime, but most importantly during the incubation/company formation, pre-seed and seed stages.

Resource Access

In addition to funding, we help our companies directly in hands-on roles and indirectly via the individuals and firms in our network throughout a company's life-cycle.

Business Development

Partnerships and collaborations with leaders of industry are the life-blood of early-stage biotech companies, and our extensive relationships help to jump start meaningful discussions through to their successful conclusions.

Access to Capital